News
MDXH
0.4749
-6.33%
-0.0321
mdxhealth says Oxford GPS-ProMPT study on GPS mdx publishes in European Urology Oncology
PUBT · 3d ago
Weekly Report: what happened at MDXH last week (0622-0626)?
Weekly Report · 3d ago
Weekly Report: what happened at MDXH last week (0615-0619)?
Weekly Report · 06/22 09:14
Weekly Report: what happened at MDXH last week (0608-0612)?
Weekly Report · 06/15 09:14
Weekly Report: what happened at MDXH last week (0601-0605)?
Weekly Report · 06/08 09:13
Weekly Report: what happened at MDXH last week (0525-0529)?
Weekly Report · 06/01 09:14
MDxHealth files Form 3 for VP, Finance and Accounting Brendan O’Connell
PUBT · 05/28 20:06
Weekly Report: what happened at MDXH last week (0518-0522)?
Weekly Report · 05/25 09:15
Mdxhealth Refocuses on Prostate Franchise Amid Headwinds
TipRanks · 05/20 06:39
Weekly Report: what happened at MDXH last week (0511-0515)?
Weekly Report · 05/18 09:15
Mdxhealth Earnings Call: Prostate Pivot Amid Pressure
TipRanks · 05/15 00:02
BUZZ-U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras
Reuters · 05/14 17:46
MDxHealth price target lowered to $5 from $9 at Lake Street
TipRanks · 05/14 15:07
MDxHealth price target lowered to $1.50 from $7 at TD Cowen
TipRanks · 05/14 15:06
Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA) and MDxHealth (MDXH)
TipRanks · 05/14 13:42
MDxHealth downgraded to Market Perform from Outperform at William Blair
TipRanks · 05/14 13:41
MDxHealth price target lowered to $4 from $7 at BTIG
TipRanks · 05/14 12:14
MDxHealth to exit the Resolve mdx business
TipRanks · 05/14 12:07
MDxHealth sees FY26 revenue $110M-$115M, consensus $118.6M
TipRanks · 05/14 12:01
BTIG Remains a Buy on MDxHealth (MDXH)
TipRanks · 05/14 10:38
More
Webull provides a variety of real-time MDXH stock news. You can receive the latest news about Mdxhealth Sa through multiple platforms. This information may help you make smarter investment decisions.
About MDXH
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.